ISIN | LU1683288770 |
---|---|
Valor Number | 38312207 |
Bloomberg Global ID | |
Fund Name | UBS (Lux) Digital Health Equity Fund UBH EUR |
Fund Provider |
UBS Asset Management (Europe) S.A.
33A avenue J.-F. Kennedy 2010 Luxembourg Web: https://www.ubs.com/lu/en.html Phone: +352-27151 |
Fund Provider | UBS Asset Management (Europe) S.A. |
Representative in Switzerland |
UBS Fund Management (Switzerland) AG Basel Phone: +41 61 288 49 10 |
Distributor(s) |
UBS AG Basel Phone: +41 61 288 75 01 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | The objective of the Subfund is to achieve the highest possible return in US dollars (Reference Currency), while taking due account of the principle of risk diversification, the security of the capital invested, and the liquidity of the assets. This Subfund aims to outperform the return of the MSCI World ESG Leaders (NR) benchmark. The Subfund is actively managed. The benchmark is used as a reference point for portfolio construction and as a basis for setting risk constraints, and/or for Performance Fee measurement purposes. The majority of the Subfund’s equity securities will not necessarily be components of or have weightings derived from the benchmark. The Investment Manager will use its discretion to significantly deviate the weighting of certain components of the benchmark and to significantly invest in companies or sectors not included in the benchmark in order to take advantage of specific investment opportunities. |
Peculiarities |
Current Price * | 105.52 EUR | 10.03.2025 |
---|---|---|
Previous Price * | 109.67 EUR | 07.03.2025 |
52 Week High * | 123.04 EUR | 19.02.2025 |
52 Week Low * | 105.48 EUR | 19.04.2024 |
NAV * | 105.52 EUR | 10.03.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 811,652,750 | |
Unit/Share Assets *** | 8,290,055 | |
Trading Information SIX |
YTD Performance | -4.19% |
31.12.2024 - 10.03.2025
31.12.2024 10.03.2025 |
---|---|---|
YTD Performance (in CHF) | -2.71% |
31.12.2024 - 10.03.2025
31.12.2024 10.03.2025 |
1 month | -11.18% |
10.02.2025 - 10.03.2025
10.02.2025 10.03.2025 |
3 months | -12.31% |
10.12.2024 - 10.03.2025
10.12.2024 10.03.2025 |
6 months | -7.71% |
10.09.2024 - 10.03.2025
10.09.2024 10.03.2025 |
1 year | -12.91% |
11.03.2024 - 10.03.2025
11.03.2024 10.03.2025 |
2 years | -6.31% |
10.03.2023 - 10.03.2025
10.03.2023 10.03.2025 |
3 years | -22.09% |
10.03.2022 - 10.03.2025
10.03.2022 10.03.2025 |
5 years | -12.69% |
10.03.2020 - 10.03.2025
10.03.2020 10.03.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
TransMedics Group Inc | 4.75% | |
---|---|---|
Zai Lab Ltd Ordinary Shares | 4.58% | |
Inspire Medical Systems Inc | 4.40% | |
Redcare Pharmacy NV | 4.32% | |
Veeva Systems Inc Class A | 4.25% | |
Zealand Pharma AS | 4.22% | |
Natera Inc | 4.06% | |
Krystal Biotech Inc | 3.65% | |
JD Health International Inc | 3.63% | |
Exact Sciences Corp | 3.54% | |
Last data update | 28.02.2025 |
TER | 1.23% |
---|---|
TER date | 31.05.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 1.50% |
Ongoing Charges *** | 1.23% |
SRRI ***
|
|
SRRI date *** | 28.02.2025 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |